Erasca, a biotech that launched in 2018 to develop cancer drugs, on Thursday announced it promoted Gary Yeung, its chief business officer, to the dual roles of chief operating and financial officer. It appointed David Chacko as its new chief business officer. Yeung previously held leadership roles at Guardant Health (NASDAQ: [[ticker:GH]]), Annexon Biosciences, and Genentech. Chacko was most recently a principal at healthcare investment firm Versant Ventures, which he joined from Alcon (NYSE: [[ticker:ALC]]).
Author: Sarah de Crescenzo
Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register.
She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.
View all posts by Sarah de Crescenzo
